RecruitingNCT07239011
Dapagliflozin added to fluoxetine for depression
About this title
Read the official source — NCT07239011Medication studyAges 18–60Egypt
Understand this study
Who could participate?
Listed age limits: 18 years to 60 years.
- Listed locations
- DamiettaSee all locations and recruitment
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: November 1, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 60
- Sponsor
- Tanta University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1 / Phase 2This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Egypt
- Age range
- From 18 Years to 60 Years
- Official registry ID
- NCT07239011
- Official title
Show the full official title
Dapagliflozin, an SGLT2 Inhibitor, From Oral Hypoglycemic Agent to Antidepressant Drug
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Damietta
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Tanta University, a university.
Does this study involve medication?
Yes. The study involves medication, including Fluoxetine and Dapagliflozin.
Who can participate?
Listed age limits: 18 years to 60 years.
Is this study still recruiting?
The registry lists this study as recruiting.
